AIZ — Assurant, Inc.

Sell-side is firmly constructive: consensus rating Buy (11 Buy / 7 Hold / 1 Sell, zero Strong Buy), and after the Aug 4, 2026 Q2 beat the 12-month targets were marked up hard — Truist to $355, UBS to $331, Piper Sandler to $329, Morgan Stanley and BMO to $320 — averaging roughly $327-328 versus the $282.46 price on 2026-09-13. Price action confirms the re-rating (six-month return of +29.25%, three-month +8.23%), though momentum has flattened recently (-1.15% over one week, +0.48% over one month) as the market waits on peak hurricane season. Note the brief's 'zero sell ratings' claim is slightly overstated — the FMP breakdown shows one sell.

Revenue has climbed for eleven consecutive quarters, from $2.774B in Q3 2023 to $3.454B in Q2 2026 (+24.5% cumulative), and YoY growth is genuinely accelerating: 6.7% (Q1'25), 8.0% (Q2'25), 8.9% (Q3'25), 7.9% (Q4'25), 11.3% (Q1'26), 9.4% (Q2'26). The more important signal is margin: operating margin bottomed at 5.10% (Q3'24) and 5.98% (Q1'25) and has recovered to 9.81% (Q1'26) and 10.91% (Q2'26) versus 9.15% in the year-ago quarter — roughly 175bp of YoY expansion, with gross margin also up ~110bp to 78.3%. That is a real inflection, not a blip: TTM net income of $1.064B is +48% versus the prior TTM window's $717M, and TTM free cash flow of $1.656B nearly doubled from $910M. The honest caveat is that a meaningful chunk of this is normalization off a catastrophe-damaged base (Q3 2024 EPS $2.55, Q1 2025 EPS $2.83) rather than a permanent step-change, and quarterly earnings are lumpy (Q4 2025 EPS $4.49 vs Q2 2026's $5.99). The -0.43% accruals ratio confirms the profit is cash-backed, not accounting-driven.

Modestly cheap on earnings, fair-to-full on everything else. At $282.46 on 2026-09-13 the stock is 13.29x TTM EPS versus its own 5-year average of 16.42x — about a 19% discount — and roughly 12.8x the ~$22.1 FY2026 consensus. PEG of 0.25 is flattered by the depressed prior-year base and shouldn't be leaned on. Against that: P/S of 1.04x is a premium to the 5-year average of 0.85x, P/B of 2.29x is full for a 7.0% ROIC / 14.9% ROE business, and the formula's ratio screener came in at a middling 54.4 (EV/EBITDA 8.56x). The earnings multiple is the most honest signal here, and it says 'cheap-ish low-beta specialty insurer,' not deep value.

This is the opposite of a stock pricing in growth that hasn't arrived. H1 2026 diluted EPS was $11.45 versus $7.39 in H1 2025 (+55%), yet as of 2026-09-13 the market pays only ~12.8x forward earnings — the earnings showed up and the multiple didn't. The catch: FY2027 consensus of $22.30 implies essentially zero growth over FY2026's ~$22.07, meaning the Street treats today's margin level as a plateau, not a launchpad, and a big slice of the YoY improvement is cat-normalization. So the setup is asymmetric around the Q3 2026 print (late Oct/early Nov): a clean cat quarter with the raised mid-single-digit growth outlook held gives room to 14-15x ($310-$330), while a bad hurricane season compresses EPS and resets the multiple lower — Q3 2024's $2.55 EPS is the template for how fast that can happen.

Range-bound/neutral with a constructive longer-term trend. As of 2026-09-13, RSI(14) was 49.93 — dead center — with price pinned to short-term averages: -0.29% vs the 20-day, +0.28% vs the 50-day, but +14.39% above the 200-day. Returns were -1.15% (1wk), +0.48% (1mo), +8.23% (3mo), +29.25% (6mo), against a 52-week range of $205.01-$303.94. Translation: the stock has digested a big move and is coiling just under its 52-week high. There's no timing edge at $282.46 — the 20/50-day at roughly $280-282 is the same as spot — so the practical approach is scaling in on any cat-driven dip toward the 200-day (~$247) and treating a decisive close above $304 as confirmation of the next leg.

• Rate path and portfolio reinvestment: AIZ's insurance investment portfolio rolls into prevailing yields, so falling short rates would trim new-money book yield and investment income, while a 'higher for longer' path supports it.
• Peak Atlantic hurricane season (Aug-Oct) is the single biggest swing factor for Global Housing — catastrophe losses plus reinsurance program cost determine whether Q3/Q4 2026 look like Q2 2026 or like Q3 2024.
• Smartphone upgrade/device-lifecycle cycle: a multi-year replacement wave is driving trade-in volume (Assurant returned $1.43B to consumers in Q2 2026 alone), which is high-margin fee revenue in Global Lifestyle and the main structural tailwind.
• Consumer credit conditions: device installment and lease receivables in the mobile business carry credit risk that would deteriorate if the labor market weakens.
• Sector rotation: with a 0.54 beta and a 1.25% dividend yield, AIZ trades defensively — it lags in risk-on rallies and holds up in drawdowns, which is a position-sizing consideration more than a fundamental one.

• Q3 2026 results, expected late October / early November 2026 — the first read on peak hurricane-season catastrophe losses and on back-to-school/holiday device volumes.
• Continued buybacks toward the upper bound of the authorization plus the $0.88/share quarterly dividend declared in August 2026; on TTM FCF of $1.656B, capital return capacity is large relative to the $14.0B market cap.
• New Global Lifestyle partner wins (e.g., the July 2026 Cogeco bundled-mobile agreement in Canada) and any further carrier/retailer expansion.
• Further upward EPS revisions — Zacks already nudged Q3 2026 to $4.48 and FY2026 to roughly $22.07 after the Q2 beat.

• Catastrophe volatility: Q3 2024 EPS of $2.55 and Q1 2025 EPS of $2.83 show a single event quarter can roughly halve run-rate earnings, and a 0.54 beta and low multiple won't fully cushion that.
• Partner concentration: Global Lifestyle economics depend on a small set of large carrier and retailer relationships; repricing or losing a major partner would hit high-margin fee income disproportionately.
• Mediocre return profile: 7.0% ROIC and a 9.9% TTM operating margin leave little buffer — precisely why the deterministic score's quality pillar came in at 48.0.
• Valuation isn't uniformly cheap: P/S of 1.04x is above the 5-year average of 0.85x and P/B of 2.29x is full if returns on capital don't keep improving.
• Consumer credit deterioration on device installment/lease receivables in a weakening labor market.

Assurant is a genuinely improving, moderately discounted specialty insurer: revenue growth accelerating to 9.4% YoY, operating margin up ~175bp YoY, TTM net income +48% and TTM FCF +82%, funded by a capital-light, fee-heavy model with low leverage (D/E 0.36) and a 1.25% dividend. The problem is that a large share of that improvement is normalization off a catastrophically weak base rather than a step-change in earning power — FY2027 consensus of $22.30 EPS implies flat growth from FY2026 — so at ~12.8x forward earnings you're being paid to wait, not being handed a fast re-rating. Verdict: hold/accumulate on weakness into the Q3 cat season, not a fresh buy at $282.46 as of 2026-09-13.

Blended forward-multiple approach: I apply ~14.3x to my FY2026 EPS estimate of ~$22.0, which sits between the current ~12.8x forward multiple and the company's own 5-year average of 16.42x — crediting the margin inflection and capital-light mix shift while discounting for catastrophe volatility and a flat FY2027 consensus of $22.30 — yielding ~$315. Cross-checks land in the same area: ~2.4x forward book value of ~$130/share ≈ $312, and ~9.0x EV/EBITDA on ~$1.8B forward EBITDA less ~$0.5B net debt ≈ $317.